tagraxofusp
Selected indexed studies
- Tagraxofusp. (, 2012) [PMID:31643455]
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. (N Engl J Med, 2019) [PMID:31018069]
- Tagraxofusp. (, 2006) [PMID:30694624]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Tagraxofusp. (2012) pubmed
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. (2019) pubmed
- Tagraxofusp. (2006) pubmed
- Tagraxofusp in myeloid malignancies. (2024) pubmed
- Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm. (2024) pubmed
- Tagraxofusp: First Global Approval. (2019) pubmed
- Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. (2020) pubmed
- Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. (2020) pubmed
- Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. (2022) pubmed
- Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval comprehensive review of the literature. (2024) pubmed